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ABSTRACT 
Amino acid mutations to agonist peptide epitopes of myelin proteins have been used to 
modulate immune responses and experimental autoimmune encephalomyelitis (EAE, 
animal model of multiple sclerosis). Such amino acid alteration are termed, altered peptide 
ligands (APL). We have shown that the agonist myelin basic protein (MBP) 87-99 epitope 
(MBP87-99) with crucial T cell receptor (TCR) substitutions at positions 91 and 96 (K91,P96 (TCR 
contact residues) to R91,A96; [R91,A96]MBP87-99) results in altered T cell responses and inhibits 
EAE symptoms. In this study, the role of citrulination of arginines in [R91,A96]MBP87-99 
peptide analog was determined using in vivo experiments in combination with 
computational studies. The immunogenicity of linear [Cit91,A96,Cit97]MBP87-99 and its cyclic 
analog - cyclo(87-99)[Cit91,A96,Cit97]MBP87-99 when conjugated to the carrier mannan 
(polysaccharide) were studied in SJL/J mice. It was found that mannocylated cyclo(87-
99)[Cit91,A96,Cit97]MBP87-99 peptide induced strong T cell proliferative responses and IFN-
gamma cytokine secretion compared with the linear one. Moreover, the interaction of 
linear and cyclic peptide analogs with the major histocompatibility complex (MHC II, H2-IAs) 
and TCR  was analyzed using molecular dynamics simulations at the receptor level, in order 
to gain a better understanding of the molecular recognition mechanisms that underly the 
different immunological profiles of citrulinated peptides compared to its agonist native 
counterpart MBP87-99 epitope. The results demonstrate that the citrulination of arginine in 
combination with the backbone conformation of mutated linear and cyclic analogs are 
significant elements for the immune response triggering the induction of pro-inflammatory 
cytokines. 
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1. Introduction 
 
 Multiple sclerosis (MS) is associated with dysregulation of the immune system, where 
auto antigens stimulate antibody and CD4+ Th1 cell responses to self antigens, such as, myelin 
basic protein (MBP), proteolytic protein and myelin oligodendrocyte glycoprotein.1, 2 This 
results in pro-inflammatory cytokines (IFN-gamma (γ), TNF-alpha) and demyelination of the 
myelin sheath. More recently, Th17 cells, secreting IL-17A and IL-17F, have been associated 
with increased risk of MS.3  
Mutated peptides, altered peptide ligands (APL), are defined as amino acid mutations 
at T cell receptor (TCR) contact residues of the wild type peptide, which alters immune 
responses, to antagonists, agonists or superagonists.4, 5 Methods into altering immune 
responses in MS, have involved APLs derived from the self autoimmune agonist (wild type) 
peptide from MBP, residues within 83-99, with the aim to shift pro-inflammatory T helper 
(Th)1 (IFN-γ) responses to the anti-inflammatory Th2 (IL-4, IL-10) responses.6-10 In fact, we 
have preciously shown, by x-ray crystallography of the MHC-peptide-TCR complex, that 
modulation of the immune response to a peptide (i.e. changing activity from TCR agonistic to 
antagonistic or superagonistic) was determined by slight changes in the interaction between 
the complementarity-determining three loops of the TCR and the altered side chains of the 
peptide epitope.4 APL in complex with MHC and/or TCR, from vesicular stomatitis virus and 
human immunodeficiency virus, only minor conformational changes in the peptide side chains 
were sufficient enough to lead to profound biological alterations.11, 12 Likewise, Likewise, APLs 
derived from the gp10044-59 epitope, associated with melanoma, when bound to HLA-DR4, 
altered the immune response. This was due to the very subtle, yet crucial changes due to the 
difference in the mode of epitope side-chain interactions with the TCR.13 In MS, APLs of the 
human immunodominant MBP83-99 or the shorter MBP87-99 epitopes have been shown to alter 
immune responses by diverting Th1 (IFN-γ) to Th2 (IL-10) profile. APLs derived from MBP83-99 
epitope were used in phase I human clinical trials with varying responses and side effects.14-17 
In addition, we previously demonstrated that linear APL of the wild type MBP87-99 with 
mutations at K91, P96 (TCR contact residues) to R91, A96; [R91, A96]MBP87-99 protected animals 
from experimental autoimmune encephalomyelitis (EAE) and it was not able to stimulate the 
encephalitogenic T cells as it did not interact strongly with TCR.18-23 Cyclization of [R91, 
A96]MBP87-99 peptide7 completely blocked the development of EAE in rats.22, 24 Using, 
peripheral blood mononuclear cells from MS patients cultured with linear or cyclic [R91, 
A96]MBP87-99 peptides altered cytokine profile of dominant Th1 cytokines to increased 
Th2/Th1 cytokine ratio.25  
 Protein citrullination is a post-translational modification of peptidyl-arginine, which 
plays a role in normal functioning of the immune system.26 However, it has been suspected 
that citrullination  plays a pathophysiological role in a number of conditions, including, 
psoriasis, chronic obstructive pulmonary disease, multiple sclerosis, inflammatory bowel 
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disease, cancer, rheumatoid arthritis and in degenerative diseases including dementia and 
Alzheimer’s disease.27 During the citrulination process, the positively charged amino acid 
Arginine (Arg) is converted into the neutral amino acid Citrulline (Cit) (Scheme 1), which is 
regulated by peptidylarginine deiminases (PAD). As a result, a non-compact structure is 
created, leading to degradation by cathepsin D. The post-translational modification of MBP, 
results in protein unfolding, degradation catalyzed by proteolytic enzymes and subsequently 
releasing new citrulinated peptide epitopes that could be immunogenic, hence, triggering 
disease (Schemes 1, 2).28-30 In fact, citrulinated proteins of MBP are present in white matter 
lesions in the central nervous system in MS.31 In addition, serum (antibodies) from patients 
with MS react to a citrulinated isomer of MBP (MBP-C8)32, as well as being recognized by CD4+ 
T cells from MS patients.33  
 SJL/J mice (H-2s haplotype; H2-IAs) is used to induce experimental autoimmune 
encephalomyelitis (an MS model in mice), as several histopathological, clinical and 
immunological outcomes mimic those of human MS.34 In SJL/J mice, residues from the 
encephalitogenic epitope MBP83-99 bind with high affinity to H2-IAs with the minimum epitope 
being MBP87-99.35 Based on the minimum binding peptide MBP87-99, we designed and 
synthesized citrulinated analogs in order to determine their immunogenic potential. We 
previously demonstrated that two citrullinated peptides, linear [Cit91,A96,Cit97]MBP87-99 (linear-
Cit) and cyclo(87-99)[Cit91,A96,Cit97]MBP87-99 (cyclic-Cit) that resulted from citrullination of 
antagonists, linear [R91,A96]MBP87-99 and cyclo(87-99)[R91,A96]MBP87-99 peptides were able to 
stimulate inflammatory Th1 polarization of peripheral blood mononuclear cells from MS 
patients.28 Herein, we studied the Immunogenicity of the two citrullinated peptides, linear-Cit 
and cyclic-Cit conjugated to KLH and reduced mannan, in SJL/J mice. We demonstrate that 
cyclic-Cit-KLH-reduced mannan induced strong T cell proliferative responses and IFN-γ 
cytokine secretion. In addition, by molecular modeling, linear-Cit and cyclic-Cit were 
compared to linear native MBP87-99 agonist peptide (linear-native), in order to gain insights in 
the molecular interactions with H2-IAs and hence the T cell receptor. These results give further 
evidence that citrulinated MBP peptides may potentially trigger disease in susceptible 
individuals.36  
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Scheme 1. Post-translational modification of Αrginine into Citrulline catalyzed by PAD. 
 
 
 
Scheme 2. Unfolding and proteolytic degradation of MBP protein as a result of citrulination. 
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2. Results and discussion 
 
 Citrullination is an enzymatic conversion of arginine to citrulline on proteins via PAD 
enzymes. The pathogenisis of MS is still not clear, however, high levels of PAD is present in the 
white matter of brain suggesting a biochemical pathway in the pathogenisis of MS.37 Several 
charged isomers of MBP exist with C1 (most common, most cationic) and C2, C3, C4, C5, C6, 
C7 and C8 the least cationic are a result of citrullination, deamindation or methylation. In MS 
patients an increase in MBP citrullination is noted in brain tissue as well as enhanced T cell 
responsiveness to MBP-C8.38 Furthermore, in rats, MBP-C8 is immunogenic resulting in T cells 
that induce experimental autoimmune encephalomyelitis. To further understand the role of 
citrullination in triggering T cells and cytokines in MS, we determined the immunogenic 
potential of citrullinated MBP87-99 peptides. Hence, linear-native, linear-Cit and cyclic-Cit 
peptides were synthesized in-house (Department of Chemistry, University of Patras, Greece) 
and were > 98 % pure as analyzed by HPLC and Electron Spray Ionization Mass Spectrometry 
(ESI-MS).  
  
2.1. Cyclic-Cit peptide-KLH-reduced mannan, induce strong T cell proliferative responses 
 
 SJL/J mice were immunized with linear-Cit and cyclic-Cit peptides, conjugated to 
keyhole limpet hemocyanin (KLH) and reduced mannan. KLH acts as a linker between peptide 
and reduced mannan. We have studied in detail the ability of mannan as a carrier to generate 
immune responses in various model systems. Mannan binds to C-type lectins, including the 
mannose receptor on antigen presenting cells,39,40 and generates immune responses to 
peptides. Spleen cells were isolated and assessed for T cell stimulation using the T cell 
proliferation assay. Mice immunized with cyclic-Cit peptide-KLH-reduced mannan, induced 
strong T cell proliferative responses when restimulated in vitro with cyclic-Cit peptide (red) or 
linear-Cit (green). Interestingly linear-native peptide did not stimulate T cell responses (blue) 
which were similar to background non-stimulated T cells (black). Mice immunized with linear-
Cit peptide-KLH-reduced mannan, and, naïve mice, did not induce T cell responses (Fig. 1). As 
the T cell epitopes used are CD4+ epitopes it is likely that CD4+ T cells are proliferating. Hence, 
cyclic-Cit peptide-KLH-reduced mannan induce srong T cell proliferative responses (Table 1).  
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Figure 1. T cell Proliferation assay from mice immunized with (A) linear-
Cit peptide-KLH-reduced mannan, (B) cyclic-Cit peptide-KLH-reduced 
mannan, or, (C) no immunization (naïve mice). Spleen cells were 
restimulated with either, cyclic-Cit peptide (red), or linear-Cit peptide 
(green), linear-native (blue), or, no recall peptide (black). Figure shows 
three mice/group where each line depicts each individual mouse. 
Individual mouse curves are shown to demonstrate variability between 
each immunized mouse. All experiments were repeated three times and 
representative data are shown. 
 
 
2.2. Cyclic-Cit peptide-KLH-reduced mannan induce strong IFN-γ and IL-4 cytokine responses 
 
 The native peptide, MBP87-99, is pathogenic in mice and humans, leading to the 
induction of Th1 pro-inflammatory cytokines. Mutating 2 TCR contact residues at positions 91, 
96, [R91,A96]MBP87-99 (altered peptide ligand, APL), changes the immunogenic profile from Th1 
to Th2 with high levels of IL-4 and lower IFN-γ41 ; citrulination of this linear and cyclic APL 
stimulates inflammatory Th1 polarization of peripheral blood mononuclear cells from MS 
patients.28 Herein, we assessed the immunogenic potential of linear and cyclic-Cit peptides in 
SJL/J mice. Spleen cells were isolated and assessed for T cell cytokine production (IFN-γ, IL-4, 
IL-10) using ELISpot assay. Mice immunized with cyclic-Cit peptide-KLH-reduced mannan 
induced strong IFN-γ and IL-4 cytokine production by T cells after recall with cyclic-Cit peptide 
(red) or linear-Cit peptide (green), and to a lesser extent after recall with linear-native peptide 
(blue) (Fig. 2A, B); no IL-10 cytokine secretion was noted (Fig. 2C). Conversely, mice 
immunized with linear-Cit peptide-KLH-reduced mannan induced low levels of IL-4 (Fig. 2B) 
but no IFN-γ or IL-10 after all recall peptides; responses were similar to non-immunized naïve 
mice (Fig. 2A, C, Table 1). This data demonstrates that dominant pro-inflammatory (Th1) 
cytokine responses are generated following immunization with cyclic-Cit peptide. In MS, pro-
inflammatory cytokine responses are one of the contributing factors to disease progression 
and demyelination. Thus, as cyclic-Cit peptide induces a strong IFN-γ response it is likely that 
citrulination may be involved in triggering of disease. To understand the mechanism of 
citrulinated peptides in disease, further detailed analysis of other cytokines, such as IL-1, IL-8, 
IL-13, IL-17 need to be measured as well as experimental autoimmune encephalomyelitis 
experiments following linear or cyclic-Cit peptide immunization need to be conducted. 
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 Figure 2. Cytokine induction (A) IFN-γ, (B) IL-4, (C) IL-10, from mice immunized with 
 linear-Cit peptide-KLH-reduced mannan, cyclic-Cit peptide-KLH-reduced mannan, or, 
 non immunized (naïve mice). Spleen cells were restimulated with either, 
 cyclic-Cit peptide (red), linear-Cit peptide (green) or linear-native peptide (blue). 
 Figure shows a representative of three mice/group where three individual mouse 
 responses are shown to show variability between each mouse. Experiments were 
 repeated 3 times.  
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Table 1. Summary of immune responses induced by peptide immunization 
__________________________________________________________________ 
Peptide conjugate      Immune response 
     T cell proliferation  IL-4 IL-10 IFN-γ 
__________________________________________________________________ 
Linear-Cit KLH-reduced mannan   -    +/-    -       - 
Cyclic-Cit KLH-reduced mannan             +     +    -       + 
Naïve control mice    -     -    -       - 
__________________________________________________________________ 
 
 
2.3. Interactions of linear-Cit, cyclic-Cit and linear-native in complex with MHC class II, H2-
IAs 
 
 Several MBP peptides with the minimal containing 87-99 sequence (MBP87-99 peptide) 
have been co-crystallized in MHC clefts. We traced these crystal structures, to study the 
binding orientation of these peptides (Table 2). They were found to bind in 2 different ways. 
In HLA-DR2b and HLA-DQ1, pockets P1, P4, P6, P9 are occupied by V87, F90, N92 and T95 
respectively (PDB IDs: 1ymm,42 1bx243 and 3pl644) as shown in Table 3, this binding mode will 
be referred to as binding pattern B. In the pattern A, present in HLA-DR2a, the peptide 
register is shifted by three residues, compared to the HLA-DR2b crystal structures and in 
which the pockets are occupied by the side chains of F90, I93, T95 and T98 (PDB IDs: 1fv1,45 
1hqr46 and 1zgl47). Binding pattern A occurs, because of the presence of G86B and K71B in 
DR2a, compared to V86B and A71B in DR2b. The result is a wider P1 and a shallower P4 
pocket in DR2a.45 In the case of binding pattern B, P4 is much wider, therefore the extended 
bulky aromatic F90 side chain has plenty of space and enters P4, resulting in this binding 
mode. H2-IAs has a similarly structured pocket to DR2b, with the main differences to HLA-
DR2b being G66A, F11B, G13B, T71B and E74B instead of D66A, P11B, R13B, A71B and A74B 
(Fig. 3A). In specific, the presence of T71B and V86B results in a wide P4 and shallow P1 
respectively. Thus, binding pattern B was considered as the predominant one and therefore 
docking of the linear-native and linear-Cit peptides within the MHC cleft of H2-IAs homology 
model, was performed accordingly.  
 In order to generate the molecular dynamics simulations starting models, the MBP87-99 
peptide was docked in the H2-IAs MHC cleft using the peptide binding pattern B from the 
HLA-DR2b (PDB ID: 1bx243) crystal structure. Citrulline and alanine residues for 
[Cit91,A96,Cit97]MBP87-99, were manually mutated in the binding site. In order to explore the 
different possibilities of the cyclic peptide’s docking orientation, it was docked in four 
different poses, with the coordinates of F90 and N92 in pockets P4 and P6 being maintained. All 
the complexes were energy minimized prior to the MD simulations.  
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Table 2. List of crystal structures with MBP peptides a containing the minimal 89-96 sequence 
binding to MHC molecules. The two different binding patterns refer to the positioning of the 
peptides in the cleft. 
______________________________________________________________________________ 
 
Haplotype MBP epitope* PDB ID Resolution (Å) Reference Binding pattern 
HLA-DR2b 83-96 1BX2 2.6 43 B 
HLA-DR2a 84-103 1FV1 1.9 45 A 
HLA-DR2a 89-98 1HQR 3.2 46 A 
HLA-DR2b 83-96 1YMM 3.5 42 B 
HLA-DR2a 87-100 1ZGL 2.8 47 A 
HLA-DQ1 84-97 3PL6 2.55 44 B 
*Numbering of MBP epitope residues refers to the numbering used in this study (V87-H88-F89-F90-K91-
N92-I93-V94-T95-P96-R97-T98-P99) 
 
 
 
Table 3. Occupation of the standard MHC defined pockets by residues present in the MBP 
analogs in the two different binding patterns observed in already crystallized complexes.  
______________________________________________________________________________ 
Binding 
Pattern P1 P2 P3 P4 P5 P6 P7 P8 P9 
A F90 K91 N92 I93 V94 T95 P96 R97 T98 
B V87 H88 F89 F90 K91 N92 I93 V94 T95 
 
 
 
The molecular dynamics simulations showed stable binding for the MBP residues 87-
95 occupying pockets P1-P9 for linear-Cit, as well as linear-native , which were both stable 
during the simulations (Fig. 3B). In both simulations of the linear peptides, residues 96-99 
appeared to have fluctuations, despite the high rigidity of the rest of the peptide which is 
deeper located in the cleft. The cyclic peptides were docked in 4 different orientations to 
determine the most favorable interacting pose. All initial cyclic peptide conformations had in 
common the occupancy of F90 and N92 in pockets P4 and P6 (Fig. 3C), in order to evaluate their 
stability in the MHC cleft. According to the RMSDs of the cyclic peptide (Fig. 3B), the second 
simulation (b) was the most stable and could provide a basis for cyclic-Cit peptide recognition 
by this specific MHC haplotype. Therefore, simulation (b) was used for the analysis regarding 
cyclic-Cit peptide binding mode. During the simulation, residues F90 and N92, occupy in a 
consistent manner the main anchor positions P4 and P6. As it can be seen in Fig. 4A, distant 
pockets P1 and P9 are not occupied due to the cyclic nature of the peptide. However, several 
other interactions, mainly hydrophobic, may assist the recognition of the cyclic-Cit peptide, 
such as the aromatic-aromatic interaction between H88 and H81B, the F89 side chain aromatic 
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ring with G58A and the hydrophobic interaction between I93 and Y61B (Fig. 4B). Side chain 
electrostatic interactions that were observed during the simulation were H88 with N82B, Cit91 
with Q70B and Cit91 with E74B (Fig. 4A).   
 Comparison of the binding modes of linear-Cit and cyclic-Cit peptides derived from 
the molecular dynamics simulations and the crystal structure of MBP85-98,48 some 
speculation can be made on their important structural elements for MHC binding. 
Superimposition of the representative MD conformations of linear-Cit and cyclic-Cit, 
compared to linear peptide were found in the MBP85-98 - HLA-DR2b crystal structure (Fig. 
4B).48 MBP85-98 and linear-Cit share many similarities in their positioning in the cleft and the 
groove anchoring pockets P1, P4, P6 and P9 are similarly occupied by side chain 
pharmacophore groups of V87, F90, N92 and T95. F90 has a side chain rotameric change due to 
the existence of V78B in the H2-IAs complex (Fig. 4A) compared to Y78B in the crystal, which 
does not allow this kind of rotation. The cyclic-Cit peptide appears to have different 
occupancies of some residues due to is conformational restrictions. Particularly, side chain 
of H88, which is positioned in between P1 and P2 and side chains V87, A96, Cit97 and T98 which 
face towards the exposed region (Fig. 4B). According to our previous work on H2-IAs,8, 9 
residues H88, F89 and K91 of the linear MBP peptide point up from the MHC groove and could 
therefore serve as TCR contacts. The effect of mutations at position 91 have been reported 
not to cause major disruptions to the structures and to the intermolecular interactions 
between the peptide and the MHC cleft.8 Based on crystal structures depicting TCR α and β 
chains, such as the different in terms of TCR binding HLA-DQ1 - MBP84-97 - Hy.1B11 TCR 
complex44, in which the TCR recognition interface is extended towards the MBP residue in 
position 96 (P96), Cit97 of our linear-Cit peptide could potentially affect TCR binding and 
therefore alter response in comparison to the linear-native peptide. 
 In the case of the cyclic peptide and in our MD simulations, Cit91 firstly interacts with 
the backbone of the peptide and more specifically backbone atoms of residues 95, 96 and 
97 and secondly with Q70B. Therefore, citrulination at position 91 should be more related to 
the stability of the cyclic peptide itself, or its affinity to H2-IAs rather than interacting with 
TCR. On the other hand, residues in cyclic-Cit peptide pointing towards the T cell recognition 
site according to our structural model are mainly V87, A96, Cit97 and T98 resulting to Cit97 
being totally exposed as a potential TCR contact residue. Cyclization by itself alters the T cell 
recognition interface of the peptide due to the aforementioned different residues being 
exposed to make contact with the TCR. Compared to the linear-Cit peptide orientation of, in 
which citrulline in position 97, is relatively distant to the MHC cleft, in the case of cyclic-Cit, 
it is well exposed to the TCR interaction interface (Fig. 4B). This totally different topology of 
the cyclic-Cit peptide could potentially lead to altered TCR recognition and is likely the 
reason for altered immune response depicted by increased levels of IFN-γ and IL-4. 
Moreover, conversion of R97 to Cit97, may differentiate T cell response through its direct 
interaction with the receptor.  
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Figure 3. (A) HLA pocket residues in HLA – MBP peptide crystal structures that are involved in 
forming the cavity for peptide recognition and their corresponding counterparts in H2-IAs. Amino 
acids are highlighted in ClustalX colors. (B) Root mean squared deviations (in transparent colors) of 
the molecular dynamics simulations of the two linear (linear-native and linear-Cit) P1-P9 occupying 
residues and cyclic-Cit in their different (a-d) binding orientations. Mean RMSD values refer to 
peptide backbone atoms and are shown in bold lines. (C) The four different starting docking positions 
of the cyclic-Cit peptide shown in orange, magenta, red and blue cartoon representation. The linear-
native and linear-Cit are shown in cyan and green respectively.   
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Figure 4. (A) Surface representation of the H2-IAs complex bound to cyclic-Cit obtained from 
molecular dynamics simulations. Surface coloring highlights hydrophobicity, i.e. white intensity 
corresponds to more hydrophobic residues. The cyclic peptide is depicted in orange color sticks 
and cartoon representation. (B) Superimposition between the representative conformations of 
simulated linear-Cit (cyan), cyclic-Cit (orange) and linear-native (green) from the HLA-DR2b crystal 
structure. 
 
 
3. Conclusion 
 
 The immunogenicity of linear-Cit and cyclic-Cit peptides in mice is a first report, which 
gives insights into the triggers of the disease. Cyclic-Cit peptide conjugated to reduced 
mannan induced strong IFN-γ and IL-4 cytokine responses and no IL-10.  Furthermore, strong T 
cell proliferative responses were observed. Interestingly, mice immunized with linear-Cit 
peptide conjugated to reduced mannan did not stimulate T cells in T proliferation assays but 
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induced weak IL-4 with no IFN-γ and IL-10 responses. These studies demonstrate that cyclic-
Cit peptide induces strong T cell responses which secrete IFN-γ and IL-4. From a structural 
point of view, this may be assumed from an altered TCR interacting interface of the cyclic-Cit 
compared to the linear-Cit peptide. This finding may open new avenues in drug design of new 
substances that inhibit PAD enzymes (citrullination) as a therapeutic strategy for the disease. 
Indeed, small molecule inhibitors of PAD enzymes have been identified using in silico 
screening of commercial libraries which reduce CD3+ T cells in mice.49  
 
4. Experimental section 
 
4.1. Solid-phase peptide synthesis of cyclic-Cit  
 
 The linear-Cit protected peptide (H-Val-His(Trt)-Phe-Phe-Cit91-Asn(Trt)-Ile-Val-Thr(tBu)-
Ala96-Cit97-Thr(tBu)-Pro-OH was synthesized on 2-chlorotrityl chloride resin (CTLR-Cl) using the 
Fmoc/tBu methodology (Scheme 3).25, 50-52 The Fmoc-protected amino acids were purchased 
from CBL (Chemical and Biopharmaceutical Laboratories, Patras, Greece). The peptide was 
synthesized manually on a 0.5 mmol scale, following convergent protocol of solid phase 
peptide synthesis, up to the final protected analog. The use of the CLTR-Cl under mild 
conditions (DCM/TFE, 7/3) for cleaving the peptide-resin bond, resulted in the release of high 
yield and purity of the protected peptide. Yield of fully protected peptide-resins was 
estimated to be 90 %. Cyclization of linear protected (Cit91,A96,Cit97)MBP87-99 (linear-Cit) was 
accomplished in liquid phase (the concentration of linear protected peptide in DMF was 10-5 
M) was achieved using O-benzotriazol-1-yl-N,N,N’,N’-tetramethyluronium tetrafluoroborate 
(TBTU) and 1-hydroxy-7-azabenzotriazole, 2,4,6 collidine in DMF solution, allowing high yield 
cyclization product (Scheme 3).7, 22, 53 The monitoring of the cyclization reaction was carried 
out using the ninhydrin test, and the reaction mixture was resolved by thin-layer 
chromatography, nbutanol/acetic acid/water (4/1/1) solvent system and analytical RP-HPLC in 
C4 Nucleosil RP column with 5μm packing material. The protected cyclic analog was then 
released from side chain protected groups using 90 % trifluoroacetic acid (TFA) in DCM 
solution containing 5 % Dithiothreitol/Triethlylsilane/water/Anisole as scavengers. Semi 
Preparative RP-HPLC for the purification of linear and cyclic peptide analogs was performed 
using a Nucleosil RP-18 reverse phase column with a 10 μm pack material 4.6x250 mm. The 
purity of cyclic peptide was estimated to be 98 % according to the analytical RP-HPLC. The 
identification of synthesized peptides was achieved by Electron Spray Ionization Mass 
Spectrometry (ESI-MS) (Figure 5).  
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Scheme 3. Synthetic procedure of cyclo(87-99)[Cit91,A96,Cit97]MBP87-99 (cyclic-Cit) peptide 
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Figure 5. (A) Analytical RP-HPLC of purified (purity 95%) cyclic-Cit analog. Column: Xbridge C18, 
150mm×4.6 mm, 3.5µm packing (Part/N= 186003034). RT: 9.49min Conditions: gradient 5% 
(B)-100% (B), in 30 min, flow rate 1 mL/min. [Eluents (a): solution TFA in H2O 0.1% (v/v), (b): 
solution TFA in AcN 0.1% (v/v)]. (B) ESI+MS of cyclic-Cit analog. M+: 1541.56, M +2H+/2: 
771.43.27, M +3H+/3: 514.38. [M +2H+/2 +K+: 790.25, M +3H+/3+ K+: 527.34]. 
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4.2. Conjugation of Reduced Mannan to linear-Cit and cyclic-Cit Peptide Analogs 
 
 The conjugation between peptide to reduced mannan was achieved following a  
previously described protocol.1, 7-10, 52, 54 Briefly, 14 mg mannan (poly-mannose from 
Saccharomyces cerevisiae, Sigma-Aldrich VIC Australia) was dissolved in 1 ml phosphate 
buffer, pH 6.0, and oxidized with sodium periodate. The oxidized form of mannan was 
purified using Sephadex G-25 M column pre-equilibrated with bicarbonate buffer pH 9.0. 
The conjugation of peptide to KLH and then to oxidized mannan was performed in 
bicarbonate buffer, pH 9.0. The reduced form of mannan was obtained after the addition of 
sodium borohydride to oxidized mannan-KLH-peptide conjugation.55-57 Previously we 
demonstrated that the conjugation efficacy of peptides or proteins to mannan via SDS-PAGE 
gels, tricine-PAGE gels and capillary electrophoresis to be 100 % conjugated.58-60 
 
4.3. Mice and Immunizations 
 
 Female 6-8 week old SJL/J mice used in all experiments, were purchased from Walter 
and Eliza Hall Institute (VIC, Australia) and housed at animal facility of AMREP, Burnet 
Institute, Australia. SJL/J mice were immunized with 50 μg of each peptide-KLH-reduced 
mannan, twice on days 0 and 14, intradermally (at the base of the tail). All studies were 
reviewed and approved by Austin Health and Alfred Health Animal Ethics Committee. 
 
4.4. Immunological assays 
 
4.4.1. ELISpot assay 
 Spleen cells from immunized SJL/J mice were isolated 14 days after the last 
immunization and assessed by ELISpot for IFN-γ, IL-4 and IL-10 secretion by T cells as 
previously described.1, 7-10, 52, 54  Spots of activity were detected using a colorimetric AP kit 
(Biorad, Hercules, CA USA) and counted using an AID ELISpot plate reader (Autoimmun 
Diagnostika GmbH, Germany).  Data are presented as mean spot forming units (SFU) per 1.0 
x 106 cells.  
 
4.4.2. Proliferation Assay 
 Spleen cells from immunized SJL/J mice were isolated 25-28 days after the second 
injection and assessed by [3H]-thymidine uptake of cells. 1 x 105 spleen cells in 100 µl of 
culture media were seeded into 96 well U-bottom plates and incubated for 1-5 days at 37 °C 
in the presence of recall peptide (10 µg/ml), ConA (internal control) or no peptide (negative 
control). ConA (internal positive control) yielded proliferation of more than 90,000 cpm and 
was excluded from the figures and no peptide (cells alone) was used as background negative 
control. [3H]-thymidine uptake was measured using a β-scintillation counter (Top Count 
Gamma Counter, Packard, USA).   
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4.5. Homology modeling 
 
 The H2-IAu complex, comprising of the MBP1–11 peptide crystal structure (PDB ID: 
1k2d; 2.20 Å resolution)61 was used as a template for the H2-IAs complex homology model 
as in previous studies.8, 9 The primary sequence of the two chains were obtained from the 
Universal Protein Resource (UNIPROT) database (UNIPROT IDs: P14437.1 and P06345.1 
respectively). The homology model was built using MODELLER v9.762 and the construction 
involved the disulfide bonds between C107 - C163 in chain A and C15 – C79 and C117 – C173 
in chain B. The overall stereochemical quality of the final model was evaluated by the 
discrete optimized energy (DOPE)63 and thorough visual inspection. 
 
4.6. Docking 
  
 The linear peptides were docked in the cleft by means of structural alignment 
according to the MBP peptide bound to HLA-DR2b (PDB ID: 1bx264) crystal structure.  In the 
case of linear-Cit residues in positions 91, 96 and 97 were mutated manually. The cyclic-Cit 
peptide was docked in four different poses. All of them retained F90 and N92 in pockets P4 
and P6 and were energy minimized using the conjugate gradient algorithm.   
  
4.7. Molecular Dynamics (MD) 
 
 All MD simulations were performed using the GROMACS software v4.5.5.65 Following 
the structural model, a minimization of the receptor topology was performed in order to 
remove steric clashes between the residues. The minimized topology was then inserted in a 
pre-equilibrated box containing water and a 0.15 M concentration of Na and Cl ions. The 
latest AMBER99SB-ILDN66 force field was used for all the dynamics simulations along with 
the TIP3P water model. Force field parameters for l-citrulline were generated using the 
general Amber force field (GAFF) and HF/6-31G*-derived RESP atomic charges.67 New, 
manual amino acid entries were added to the forcefield parameters in order to enable 
cyclization. Each system consisted of the protein, the peptide, ~15,000 water molecules and 
~130 ions in an 8x8x8 nm simulation box. The 6 model systems were energy minimized and 
subsequently subjected to a 10 ns MD equilibration, with positional restraints on protein 
coordinates. These restraints were released, and 500 ns MD trajectories were produced in 
constant temperature of 300 K using separate v-rescale thermostats for the protein, the 
peptide and solvent molecules. A time step of 2 fs was used and all bonds were constrained 
using the LINCS algorithm. Lennard-Jones interactions were computed using a cut-off of 10 
Å, and the electrostatic interactions were treated using PME with the same real-space cut-
off.  
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